Downloads
Abstract
Background: The incidence of neutropenia following chemotherapy in breast cancer with Docetaxel, Doxorubicin, Cyclophosphamide (TAC) regimen is quite high and impairs patients’ quality of life. Colony- stimulating factors including Pegfilgrastim, a long acting form of Filgrastim, induced decreasing febrile neutropenia rate.
Patients and method: Non- randomized, prospective, descriptive, open- label research to assess the efficacy and safety profile of one- per- cycle Pegfilgrastim.
Results: 31 breast cancer patient received adjuvant or palliative treatment. Toxicity was recorded on clinical examination and work-up. 30/31 (97%) of patients completed 6 cycles. The duration of febrile neutropenia was from 2- 5 days. The rate of dosage compliance was 75.2% (23/31). 10/31 patients (32%) complained mild or severe bone pain after receiving Pegfilgrastim for 3-5 days. 30/31 (97%) patients completed 6 cycles. Febrile neutropenia’s rate and neutropenia was 6.4% and 16.1%, respectively.
Conclusion: Pegfilgrastim was a renovate form of the colony-stimulating factors, reducing the need of daily injection. It decreased febrile neutropenia risk in almost breast cancer patients treated TAC regimen in this series.
References
Bonadonna G., Moliterni A., Zambetti M., et al. (2005), “30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study”, BMJ, 330 (7485), p. 217.
Chirivella I., Bermejo B., Insa A., et al. (2009), “Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients”, Breast Cancer Res Treat, 114 (3), p. 479-84.
Fumoleau P., Chevallier B., Kerbrat P., et al. (1996), “A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer- Report of the Clinical Screening Group of the EORTC*”, Annals of Oncology, 7, p. 165-171.
J Crawford, H Ozer and R Stoller (1991), “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer”, Engl J Med, 325, p. 164-170.
Kirshner J. J., Heckler C. E., Janelsins M. C., et al. (2012), “Prevention of pegfilgrastim- induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base”, J Clin Oncol, 30 (16), p. 1974-9.
Kuderer N. M., Dale D. C., Crawford J., et al. (2007), “Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review”, J Clin Oncol, 25 (21), p. 3158-67.
Martin M., Lluch A., Segui M. A., et al. (2006), “Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen”, Ann Oncol, 17 (8), p. 1205-12.
Miguel Martin M.D., Tadeusz Pienkowski, M.D., John Mackey, M.D.,, Marek Pawlicki M.D., Jean-Paul Guastalla, M.D., Charles Weaver, M.D.,, Eva Tomiak M.D., Taher Al- Tweigeri, M.D., Linnea Chap, M.D., Eva Juhos, M.D.,, et al. (2005), “Adjuvant Docetaxel for Node-Positive Breast Cancer”, Thenew england journal of medicine, 352 (22), p. 2302-2313.
Molineuxa Graham, Kinstlera Olaf, Briddella Bob, et al. (1999), “A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans”, Experimental Hematology 27, p. 1724–1734.
Montella L., Addeo R., Guarrasi R., et al. (2010), “Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel epidoxorubicin/ cyclophosphamide”, Eur J Cancer Care (Engl), 19 (2), p. 200-4.
O’Donnell P. H. and Dolan M. E. (2009), “Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy”, Clin Cancer Res, 15 (15), p. 4806-14.
Sang Nguyen Thi (2016), “Đánh giá kết quả hóa trị bổ trợ phác đồ tác trong bệnh ung thư vú giai đoạn II, IIIa hạch nách dương tính tại Bệnh viện K”,
Smith R. E., Anderson S. J., Brown A., et al. (2002), “Phase II trial of doxorubicin/docetaxel/ cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58”, Clin Breast Cancer, 3 (5), p. 333-40.
Smith T. J., Bohlke K., Lyman G. H., et al. (2015), “Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update”, J Clin Oncol, 33 (28), p. 3199-212.
Vogel C. L., Wojtukiewicz M. Z., Carroll R. R., et al. (2005), “First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study”, J Clin Oncol, 23 (6),p. 1178-84.
Von Minckwitz G., Schwenkglenks M., Skacel T., et al. (2009), “Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis”, Eur J Cancer, 45 (4),p. 608-17.
Welte Karl, Gabrilove Janice, Bronchud Miguel H., et al. (1996), “Filgrastim (r-metHuG-CSF)- The First 10 Years”, Blood, 88 (6), p. 1907-1929.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital